Twist Bioscience Corp (TWST) financials: revenue, earnings and cash flow
Fiscal 2017–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Twist Bioscience’s revenue went from $11M in fiscal 2017 to $377M in fiscal 2025, growth of about 55.9% a year.
Net income in fiscal 2025 was -$78M, a net margin of -20.6%; the best year in this period was 2017 with -$59M.
Over the twelve months to September 30, 2026, revenue was $459M and net income -$130M.
Free cash flow was -$76M in fiscal 2025 and positive in 0 of the 9 years shown.
The diluted share count rose 2369% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $459M | $377M | $313M | $245M | $204M | $132M | $90M | $54M | $25M | $11M |
| Gross profit | — | $191M | $133M | $90M | $84M | $52M | $29M | $7M | -$7M | -$13M |
| Operating income | — | -$136M | -$221M | -$217M | -$235M | -$153M | -$140M | -$109M | -$71M | -$58M |
| Net income | -$130M | -$78M | -$209M | -$205M | -$218M | -$152M | -$140M | -$108M | -$71M | -$59M |
| EPS (diluted) | $-2.08 | $-1.30 | $-3.60 | $-3.60 | $-4.04 | $-3.15 | $-3.57 | $-3.92 | $-0.03 | $-24489.86 |
| R&D | — | $80M | $91M | $107M | $120M | $69M | $43M | $36M | $20M | $19M |
| Revenue growth | — | +20.3% | +27.7% | +20.4% | +53.8% | +46.9% | +65.7% | +113.9% | +136.2% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | — | -$48M | -$64M | -$142M | -$124M | -$112M | -$142M | -$88M | -$66M | -$51M |
| Capital spending | — | -$28M | -$5M | -$28M | -$102M | -$27M | -$10M | -$15M | -$4M | -$7M |
| Free cash flow | — | -$76M | -$69M | -$170M | -$226M | -$139M | -$152M | -$103M | -$70M | -$58M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | — | $64M | $51M | $30M | $80M | $37M | $17M | $11M | $3M | $2M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $232M | $276M | $336M | $505M | $478M | $290M | $138M | $81M | $31M |
| Debt | — | $76M | $85M | $94M | $95M | $63M | $36M | $8M | $10M | — |
| Equity | — | $473M | $473M | $623M | $789M | $581M | $336M | $152M | -$201M | -$133M |
| Total assets | — | $642M | $614M | $776M | $961M | $702M | $399M | $187M | $116M | — |
| Shares (diluted) | 63M | 60M | 58M | 57M | 54M | 48M | 39M | 27M | 3M | 2M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | 50.7% | 42.6% | 36.6% | 41.4% | 39.1% | 31.9% | 12.8% | -26.6% | -123.1% |
| Operating margin | — | -36.2% | -70.6% | -88.6% | -115.3% | -115.4% | -155.5% | -200.2% | -277.5% | -543.2% |
| Net margin | -28.3% | -20.6% | -66.7% | -83.5% | -107.0% | -114.9% | -155.3% | -198.0% | -280.2% | -550.9% |
| FCF margin | — | -20.1% | -22.1% | -69.5% | -111.1% | -105.3% | -168.8% | -188.8% | -274.7% | -537.7% |
| ROIC | — | -19.6% | -31.3% | -23.9% | -25.3% | -23.4% | -29.7% | -53.8% | — | — |
| ROE | — | -16.4% | -44.2% | -32.8% | -27.6% | -26.2% | -41.6% | -70.8% | 35.4% | 44.5% |
Frequently asked questions
What is Twist Bioscience’s annual revenue?
$377M in fiscal 2025 and $459M over the twelve months to September 30, 2026.
How much profit does Twist Bioscience make?
Net income was -$78M in fiscal 2025 (net margin -20.6%).
Is Twist Bioscience’s revenue growing?
Yes: revenue rose 20.3% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.